Navigation Links
Omeros Unlocks Four Additional Orphan GPCRs
Date:9/13/2011

SEATTLE, Sept. 13, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR15, GPR39, GPR78 and GPR161. Omeros has now announced that it has unlocked 14 of the 80 Class A orphan GPCRs. GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros, which expects to unlock a large percentage of these for drug development, is initially targeting Class A orphan GPCRs.

The four unlocked orphan receptors announced today are linked to a wide range of indications and present multiple new opportunities for drug development by the pharmaceutical industry. GPR15 has been associated with rheumatoid arthritis and HIV-mediated enteropathy, a chronic intestinal illness in HIV-infected patients. GPR39 has been implicated in the pathogenesis of obesity-related type-2 diabetes and esophageal squamous cell carcinoma, the most prevalent esophageal cancer worldwide. GPR78 has been linked to bipolar affective disorder and schizophrenia, and GPR161 has been tied to congenital cataracts and birth defects of the brain and spinal cord.  

"These discoveries further validate our proprietary technology and underscore our unique ability to open to the pharmaceutical industry previously inaccessible targets for drug development," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Each of these receptors is linked to severe medical disorders, and our success enables the design of novel compounds that could result in new and more effective therapies for patients that need them."

Ongoing GPCR Program

Omeros has begun screening orphan GPCRs against its small-molecule chemica
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
2. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
3. Omeros Announces Clinical Development Programs for OMS103HP and OMS302
4. Omeros Corporation Reports First Quarter 2011 Financial Results
5. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
6. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
7. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
8. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
9. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
10. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
11. Omeros Announces Publication of Data From Antifibrinolytic Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...
(Date:5/23/2013)... SAN DIEGO and PARIS ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today ... V asodilator I ndependent S tenosis ... late breaking clinical trial session at EuroPCR 2013. These ...
(Date:5/23/2013)... LAUSANNE , Switzerland ... 23, 2013 Cenix BioScience, ... developer specialized in RNAi-, miRNA- and high content-driven ... biopharmaceutical group of companies with a focus on ... medical needs, including oncology and companion diagnostics, today ...
Breaking Medicine Technology:BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:5/23/2013)... 23, 2013 Jim Fitzpatrick just did ... Advertising developed yet another outside-of-the-box approach to reaching the ... he brings daily newscasts to the retail automotive industry, ... of a broadcast news format. , CBTNews.com is ... news. Co-anchors Bridget Everett and Russell Brown host the ...
(Date:5/23/2013)... 23, 2013 To better serve ... company, is pleased to announce the release of ... its pacesetting space division products. Provided by Koroseal, ... the new patterns and colors represent a sophisticated ... meetings with a team of Koroseal experts, Modernfold ...
(Date:5/23/2013)... now, little was scientifically known about the human potential ... for people who are suffering in a way that ... researchers at the Center for Investigating Healthy Minds at ... that adults can be trained to be more compassionate. ... Psychological Science , is the first to investigate whether ...
(Date:5/23/2013)... New techniques in imaging of brain activity developed ... Neurological Institute, and his colleagues lead to improved ... combination of electroencephalogram (EEG) and functional magnetic resonance ... the areas generating epileptic seizures, giving neurosurgeons a ... if appropriate. These results were presented at ...
(Date:5/23/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Physicians ... lung cancer now have more information to help with the ... that low-dose CT scans pick up significantly more lung tumors ... of smoking are at high risk for lung cancer, the ... have to consider the potential harm of radiation exposure when ...
Breaking Medicine News(10 mins):Health News:Fitzpatrick Advertising Founder Brings Auto Industry into Focus with CBT News 2Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:Study shows people can be trained to be more compassionate 2Health News:Study shows people can be trained to be more compassionate 3Health News:Study shows people can be trained to be more compassionate 4Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... Two stroke-prevention procedures are safe and equally beneficial for ... effectiveness does vary by age, say researchers at the ... other North American stroke investigators. In findings reported ... Antonio, Texas, the researchers say physicians now have better ...
... on routes they knew well , FRIDAY, Feb. 26 ... drivers can make fatal mistakes on familiar routes, German ... brain activity in 16 experienced and 16 less experienced ... the routes on the simulator, the participants, brains were ...
Cached Medicine News:Health News:Stroke Conference Daily News Summary -- Friday 2Health News:Stroke Conference Daily News Summary -- Friday 3Health News:Stroke Conference Daily News Summary -- Friday 4Health News:Stroke Conference Daily News Summary -- Friday 5Health News:Stroke Conference Daily News Summary -- Friday 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 2Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 3Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 4Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 5Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 7Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 2Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 4Health News:American National Announces Corrected Dividend Dates 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 3
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
The Pivot Bipolar was designed with a simple one-step assembly interface between the femoral head and the compression molded liner which requires no instruments and reduces OR time....
Medicine Products: